{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:20:05Z","timestamp":1792790405242,"version":"4.5.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors have improved the survival in patients affected by an increasing number of malignancies, but they may also trigger various autoimmune side-effects, including endocrinopathies. Very rarely, immune checkpoint inhibitors have been reported to cause central diabetes insipidus. However, with their expanding use, the likelihood that oncologists will face this endocrine adverse event is expected to increase. By reviewing the limited literature on central diabetes insipidus induced by immune checkpoint inhibitors, some inconsistencies emerge in the diagnosis and the management of patients presenting with this toxicity, together with difficulties related to classifying its severity. Until now, specific guidelines on the management of central diabetes insipidus induced by immune checkpoint inhibitors are lacking. In clinical practice, endocrinological consultation may relieve medical oncologists from difficulties in treating this side-effect; oncologists, however, remain responsible for its early diagnose and the management of the causative drugs. To this aim, some practical suggestions are advised for the multidisciplinary management of cancer patients presenting with central diabetes insipidus induced by immune checkpoint inhibitors.<\/jats:p>","DOI":"10.3389\/fonc.2022.798517","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T06:45:15Z","timestamp":1646289915000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?"],"prefix":"10.3389","volume":"12","author":[{"given":"Agnese","family":"Barnabei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Strigari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Corsello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria","family":"Paragliola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Falzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salvatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore Maria","family":"Corsello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Torino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.12766","article-title":"Immune Checkpoint Inhibitors: The Linchpins of Modern Immunotherapy","volume":"290","author":"Wilky","year":"2019","journal-title":"Immunol Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra17034812","article-title":"Immune-Related Adverse Events Associated With Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1055\/a-0843-3366","article-title":"A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated With Immune Checkpoint Inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/cen.13866","article-title":"Diagnosis and Management of Central Diabetes Insipidus in Adults","volume":"90","author":"Garrahy","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309023291002","article-title":"Lymphocytic Infundibuloneurohypophysitis as a Cause of Central Diabetes Insipidus","volume":"329","author":"Imura","year":"1993","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.9.5945","article-title":"A Longitudinal Study of Vasopressin Cell Antibodies, Posterior Pituitary Function, and Magnetic Resonance Imaging Evaluations in Subclinical Autoimmune Central Diabetes Insipidus","volume":"84","author":"De Bellis","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020791","article-title":"Central Diabetes Insipidus and Autoimmunity: Relationship Between the Occurrence of Antibodies to Arginine Vasopressin-Secreting Cells and Clinical, Immunological, and Radiological Features in a Large Cohort of Patients With Central Diabetes Insipidus of Known and Unknown Etiology","volume":"88","author":"Pivonello","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.8.8757","article-title":"Longitudinal Study of Vasopressin-Cell Antibodies and of Hypothalamic-Pituitary Region on Magnetic Resonance Imaging in Patients With Autoimmune and Idiopathic Complete Central Diabetes Insipidus","volume":"87","author":"De Bellis","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","article-title":"Posterior Pituitary","volume-title":"Williams Textbook of Endocrinology","author":"Robinson","year":"2015"},{"key":"B11","unstructured":"GubbiS\n            Hannah-ShmouniF\n            KochCA\n            VerbalisJG\n            FeingoldKR\n            AnawaltB\n          Diagnostic Testing for Diabetes Insipidus"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803760","article-title":"A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus","volume":"379","author":"Fenske","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31255-3","article-title":"Arginine-Stimulated Copeptin Measurements in the Differential Diagnosis of Diabetes Insipidus: A Prospective Diagnostic Study","volume":"394","author":"Winzeler","year":"2019","journal-title":"Lancet"},{"key":"B14","first-page":"751","volume-title":"Clinical Physiology of Acid-Base and Electrolyte Disorders","author":"Rose","year":"2001"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.153.5.1033","article-title":"Frequency and Variation of the Posterior Pituitary Bright Signal on MR Images","volume":"153","author":"Brooks","year":"1989","journal-title":"Am J Neuroradiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00234-018-2072-7","article-title":"Neuroimaging of Central Diabetes Insipidus-When, How and Findings","volume":"60","author":"Adams","year":"2018","journal-title":"Neuroradiology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820201)49:3<596::aid-cncr2820490332>3.0.co;2-8","article-title":"Bronchogenic Carcinoma and Diabetes Insipidus: Case Report and Review","volume":"49","author":"Krol","year":"1982","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01226-4","article-title":"Immune Checkpoint Inhibitor-Associated Pituitary Adverse Events: An Observational, Retrospective, Disproportionality Study","volume":"43","author":"Bai","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1530\/EDM-20-0123","article-title":"Diabetes Insipidus Secondary to Nivolumab-Induced Neurohypophysitis and Pituitary Metastasis","volume":"2021","author":"Fosci","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 Antibody Therapy Associated Autoimmune Hypophysitis: Serious Immune-Related Adverse Events Across a Spectrum of Cancer Subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0105","article-title":"Ipilimumab-Induced Hypophysitis and Uveitis in a Patient With Metastatic Melanoma and a History of Ipilimumab-Induced Skin Rash","volume":"12","author":"Nallapaneni","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.582394","article-title":"Case Report: Ipilimumab-Induced Panhypophysitis: An Infrequent Occurrence and Literature Review","volume":"1","author":"Barnabei","year":"2020","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-17-0146","article-title":"Combination Immune Checkpoint Inhibitor Therapy Nivolumab and Ipilimumab Associated With Multiple Endocrinopathies","volume":"2018","author":"Gunawan","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"144 (abstract 323)","DOI":"10.1097\/01.ccm.0000619648.08126.8f","article-title":"Diabetes Insipidus in Checkpoint Inhibitor Treatment and Acute Myeloid Leukemia","volume":"48","author":"Grami","year":"2020","journal-title":"Crit Care Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01905","article-title":"Anti-PD-L1 Treatment-Induced Central Diabetes Insipidus","volume":"103","author":"Zhao","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106427","article-title":"Central Diabetes Insipidus Related to Anti-PD1 Protein Active Immunotherapy","volume":"83","author":"Deligiorgi","year":"2020","journal-title":"Int Immunopharm"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0334","article-title":"Anti-PD-1 Treatment-Induced Immediate Central Diabetes Insipidus: A Case Report","volume":"13","author":"Yu","year":"2021","journal-title":"Immunotherapy"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000221","article-title":"Permanent Diabetes Insipidus in a Patient With Mesothelioma Treated With Immunotherapy","volume":"64","author":"Brilli","year":"2020","journal-title":"Arch Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.09.016","article-title":"Hypothalamitis and Severe Hypothalamic Dysfunction Associated With Anti-Programmed Cell Death Ligand 1 Antibody Treatment","volume":"104","author":"Tshuma","year":"2018","journal-title":"Eur J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000293","article-title":"Endocrinological Side-Effects of Immune Checkpoint Inhibitors","volume":"28","author":"Torino","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"B31","unstructured":"PreteA\n            SalvatoriR\n          Hypophysitis2018"},{"key":"B32","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights Into Pathogenesis From an Autopsy Series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/pin.13161","article-title":"An Autopsy Case Study of Lymphocytic Hypophysitis Induced by Nivolumab Treatment for Esophageal Malignant Melanoma","volume":"10","author":"Okabe","year":"2021","journal-title":"Pathol Int"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG Subclasses and Allotypes: From Structure to Effector Functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nature01621","article-title":"Association of the T-Cell Regulatory Gene CTLA4 With Susceptibility to Autoimmune Disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-med-053013-053944","article-title":"Pharmacogenetics of Cancer Drugs","volume":"66","author":"Hertz","year":"2015","journal-title":"Annu Rev Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14609","article-title":"Pharmacogenetics for Severe Adverse Drug Reactions Induced by Molecular-Targeted Therapy","volume":"111","author":"Udagawa","year":"2020","journal-title":"Cancer Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001073","article-title":"Th17 Cells Contribute to the Pathology of Autoimmune Hypophysitis","volume":"206","author":"Chalan","year":"2021","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.10.006","article-title":"Evidence for Interleukin 17 Involvement in Severe Immune-Related Neuroendocrine Toxicity","volume":"141","author":"Mazzarella","year":"2020","journal-title":"Eur J Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0232-2","article-title":"Hypothalamic Expression of PD-L1: Does It Mediate Hypothalamitis","volume":"16","author":"Iervasi","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/JC.2014-4209","article-title":"Rabphilin-3A as a Targeted Autoantigen in Lymphocytic Infundibulo-Neurohypophysis","volume":"100","author":"Iwama","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0707-6","article-title":"Lymphocytic Infundibulo-Neurohypophysitis: A Clinical Overview","volume":"50","author":"Johnston","year":"2015","journal-title":"Endocrine"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ20-0436","article-title":"Anti-Pituitary Antibodies as a Marker of Autoimmunity in Pituitary Glands","volume":"67","author":"Iwama","year":"2020","journal-title":"Endocr J"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1962","article-title":"Pituitary Dysfunction in Granulomatosis With Polyangiitis: The Mayo Clinic Experience","volume":"99","author":"Kapoor","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4137\/CCRep.S15352","article-title":"A Case of IgG4-Related Hypophysitis Presented With Hypopituitarism and Diabetes Insipidus","volume":"8","author":"Harano","year":"2015","journal-title":"Clin Med Insights Case Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0773-7","article-title":"Critical Review of IgG4-Related Hypophysitis","volume":"20","author":"Shikuma","year":"2017","journal-title":"Pituitary"},{"key":"B48","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1634\/theoncologist.2019-0083","article-title":"Diagnosis and Management of Rare Immune-Related Adverse Events","volume":"25","author":"Schoenfeld","year":"2020","journal-title":"Oncologist"},{"key":"B49","unstructured":"Common Terminology Criteria for Adverse Events. Version 5.0. Bethesda, MD: National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services2017"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B51","unstructured":"NCCN Guidelines\u00ae for Management of Immunotherapy-Related Toxicities in NCCN Guidelines for Supportive Care. Version 2.2021"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immune Checkpoint Inhibitor-Related Adverse Events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of Toxicities From Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2213-y","article-title":"Ipilimumab-Induced Endocrinopathies: When to Start Corticosteroids (or Not)","volume":"72","author":"Corsello","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1634\/theoncologist.2018-0470","article-title":"Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management","volume":"25","author":"Del Rivero","year":"2020","journal-title":"Oncologist"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.798517\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T06:45:18Z","timestamp":1646289918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.798517\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":55,"alternative-id":["10.3389\/fonc.2022.798517"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.798517","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]},"article-number":"798517"}}